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Abstract
Purpose Recently a combination of paclitaxel and carbo-
platin (TC) (without an anthracycline) has begun to be used
as an adjuvant or remission induction therapy, without any
critical supportive evidence of its eYcacy relative to a com-
bination chemotherapy of taxane, platinum and anthracy-
cline such as TEC (paclitaxel, epirubicin and carboplatin).
The aim of our present study was to conduct the required
clinical evaluations of the relative eVectiveness of TC com-
pared to TEC.
Methods A retrospective comparison between the eYcacy
of TEC and TC regimens used for endometrial carcinoma at
the Osaka University Hospital and the Osaka Medical Cen-
ter for Cancer and Cardiovascular Diseases in Osaka,
Japan, respectively, from 1999 to 2009 was performed. The
clinical characteristics of the patients who received either
TEC or TC were not signiWcantly diVerent, and TEC and
TC therapies were initiated based on similar indications for
chemotherapy. TEC regimen was paclitaxel (150 mg/m2),
epirubicin (50 mg/m2) and carboplatin (AUC 4). TC regi-
men consisted of paclitaxel (175 mg/m2) and carboplatin
(AUC 5).
Results TEC was demonstrated to provide signiWcantly
better survival than TC as an adjuvant therapy for resected
Stage III/IV diseases (p = 0.017 for progression-free sur-
vival and p = 0.014 for overall survival, by the log-rank
test). However, in recurrent or more advanced cases, TC
and TEC demonstrated similar eVects on survival (p = 0.55
for progression-free survival and p = 0.63 for overall
survival).
Conclusions TEC should be oVered as an adjuvant ther-
apy to Stage III/IV patients. TC may be considered for
recurrent or unresectable cases as a remission induction
therapy.
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Abbreviations
TAP or AP Doxorubicin and cisplatin 
(with or without paclitaxel)
TC or TEC Paclitaxel and carboplatin 
(without or with epirubicin)
TEP Paclitaxel, epirubicin and cisplatin
ALT Alanine aminotransferase
AST Aspartate aminotransferase
AUC Area under the plasma drug concentration
versus time curve
CR Complete response
G-CSF Granulocyte-colony stimulating factor
GOG Gynecologic Oncology Group
5-HT3 5-Hydroxytriptamine-3
JGOG Japanese Gynecologic Oncology Group
OS Overall survival
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Endometrial cancer is the most common gynecological can-
cer in the United States, and its incidence has increased sig-
niWcantly during the last three decades. Current surgical
endometrial cancer therapy consists of a hysterectomy,
bilateral salpingo-oophorectomy and retroperitoneal lymph
node dissection [1, 2]. A randomized study by the Gyneco-
logic Oncology Group (GOG) revealed that a combination
chemotherapy of AP (doxorubicin and cisplatin) was supe-
rior to the traditional whole abdominal irradiation as an
adjuvant therapy (GOG #122). Unfortunately, signiWcant
hematological and cardiac toxicity and treatment-related
death was soon associated with AP treatments [3].
Platinum and anthracycline have long been used as the
gold standard drugs for advanced or recurrent endometrial
carcinomas [4, 5]. Recently, taxane has been added to this
group [6, 7]. A recent study showed better survival follow-
ing a TAP therapy (paclitaxel, doxorubicin and cisplatin)
than for AP (GOG #177) [8]; however, neurological toxic-
ity was even greater for patients receiving TAP, with 39%
of the patients suVering Grade 2–3 peripheral neuropathy.
Lissoni et al. [9] reported that TEP (paclitaxel, epirubi-
cin and cisplatin) exhibited superior anti-tumor activity
against advanced endometrial carcinoma. Recently, TEC
(paclitaxel, epirubicin and carboplatin) was shown to have
improved activity against metastatic and recurrent endome-
trial carcinomas, and was found to be relatively tolerable
when given with G-CSF support [10]. In our own recent
phase I/II prospective studies of TEC, we analyzed the opti-
mal dose for TEC therapy of our Japanese population,
which we subsequently determined to be 150 mg/m2 paclit-
axel, 50 mg/m2 epirubicin, and AUC 4 carboplatin Takata
et al. [18]. Based on these Wndings, TEC has become our
new standard for endometrial carcinoma treatment.
Recently, however, TC (paclitaxel and carboplatin) has
been begun to be widely applied for treatment of endome-
trial carcinoma, based on its initial reported eVectiveness
and high tolerability [11–13]. However, its equivalency or
superiority to TEC has never been rigorously demonstrated,
thus TC therapy is not currently an established regimen for
endometrial carcinoma.
Gynecologic Oncology Group (GOG) has an ongoing
study (#209) to compare TC with TAP, and the Japanese
Gynecologic Oncology Group (JGOG) is performing a sim-
ilar prospective study (JGOG #2043) to compare three
combination chemotherapies: TC, DP (docetaxel and
cisplatin) and AP. It has been of great interest to gynecolo-
gists whether TC alone is a suYcient chemotherapy for
endometrial carcinoma or whether anthracycline is addi-
tionally required.
In our present study, we performed a retrospective com-
parison of TEC versus TC against endometrial carcinoma.
We compared the patients’ data for TEC therapy, which
was exclusively performed at the Osaka University Hospi-
tal as part of our phase II study of TEC therapy (submitted),
with those of TC, which was administered at our sister
Osaka Medical Center for Cancer and Cardiovascular
Diseases.
Materials and methods
A retrospective comparison was conducted between the rel-
ative eYcacies of the TEC and TC regimens, which were
performed for endometrial carcinoma cases at the Osaka
University Hospital and the Osaka Medical Center from
1999 to 2009. During this period, TEC therapy was exclu-
sively used at the Osaka University Hospital for all its
endometrial carcinoma cases with indications for chemo-
therapy. A TEC dosage of 150 mg/m2 for paclitaxel,
50 mg/m2 for epirubicin and AUC 4 for carboplatin was
used, based on our phase I results with a Japanese popula-
tion (submitted). On the other hand, at the Osaka Medical
Center, a TC regimen of paclitaxel 175 mg/m2 and carbo-
platin AUC 5 (based on the results of our phase I study for
ovarian carcinoma in a Japanese population, preliminarily
reported by Ueno et al. [14]) was used instead of TEC for
all their endometrial carcinoma cases with indications for
chemotherapy. The gynecologic surgeons who performed
the surgical treatments were all trained at the Osaka Uni-
versity Hospital, and the surgical procedures, and the indi-
cations for pelvic and para-aortic lymph node dissection,
were identical in the two hospitals. Moreover, adjuvant
chemotherapy was performed using the similar indicators.
Eligibility for TEC and TC chemotherapies required that the
patient have adequate Wndings in the following: hematology
(WBC ¸3,000/l, platelets ¸100,000/l, granulocytes
¸1,500/l and hemoglobin ¸10 g/dl), renal (creatinine
¸2 mg/dl) and hepatic [bilirubin ¸3 mg/dl, aspartate ami-
notransferase (AST) and alanine aminotransferase (ALT)
¸2 times the international normal value]. A relative perfor-
mance status of 0–2 was needed. The tumors needed to be
histopathologically diagnosed as being either a primary or
recurrent endometrial carcinoma. In the current study, the
clinicopathological features of the cases in which TEC or
TC chemotherapy were performed, including the age of the
patient, the histology and the stage of the disease, and
the adverse eVects of each chemotherapy regimen were
retrospectively reviewed utilizing their clinical records,123
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operative records, and histopathology reports. The histolog-
ical diagnoses were made by authorized pathologists from
the Departments of Pathology of the Osaka University and
the Osaka Medical Center, who were all trained at the
Osaka University Hospital.
In order to evaluate the eYcacy of TEC and TC chemo-
therapies against endometrial carcinoma, progression-free
survival (PFS) and overall survival (OS) were calculated.
PFS was measured from the administration of chemother-
apy to the date of the radiologic or pathologic diagnosis of
relapse, or to the date of the last follow-up. OS was deWned
as the period from the start of chemotherapy to the patient’s
disease-speciWc death or to the date of the last follow-up. In
order to evaluate the anti-tumor eVect of TEC and TC
chemotherapies against the advanced diseases which were
unresectable by surgery and the recurrent diseases, previ-
ously described standard criteria from the World Health
Organization [15] and Pectasides et al. [16] were used. The
tumors were assessed by CT scan and/or MRI at baseline
and every three treatment courses thereafter. A complete
response (CR) was deWned as the disappearance of all
known disease, determined by two observations not less
than 4 weeks apart. We used RECIST (Response Evalua-
tion Criteria in Solid Tumors, version 1.0) for evaluating
the therapy response. A CR required regression of all
tumors. A partial response (PR) required >30% reduction in
the largest diameter of the largest lesion. A progressive dis-
ease (PD) was deWned as one in which new lesions
appeared, or the largest diameter of the largest lesion
enlarged more than 20%. All others were considered to be
stable disease (SD).
Adverse treatment eVects were also analyzed. They were
graded based on the National Cancer Institute’s Common
Toxicity Criteria (version 2.0). Granulocyte-colony stimu-
lating factor (G-CSF) was administered to improve immune
function whenever the total WBC/neutrophil count
decreased to under 1,000/500 per l, or when febrile neu-
tropenia was observed. A histamine H1 5-HT3 antagonist
was administrated orally before the paclitaxel to prevent
both emesis and an allergic reaction. Other antiemetic drugs
were administered as needed.
A regimen of either TEC or TC was administered every
3–4 weeks for 3 weeks against resected Stage I/II diseases
with risk factors, which included a myometrium invasion
depth of >1/2 and or an atypical histology (such as endome-
trioid adenocarcinoma Grade 3, clear cell carcinoma or
serous papillary carcinoma). TEC or TC was given as an
adjuvant therapy for 6 weeks against resected Stage III/IV
diseases and unresectable or recurrent diseases. The cases
which were classiWed as Stage IIIa due to positive perito-
neal cytology alone, without any other risk factors, were
excluded from as having an indication for adjuvant chemo-
therapy. In order to compare the eYcacy of TEC and TC
regimes accurately, all the cases in which these chemother-
apies were attempted were included in this analysis, includ-
ing the cases in which these chemotherapies were canceled
underway due to severe toxicities or to the patient’s inter-
mittent desire to stop chemotherapy.
The Osaka University Hospital protocol for TEC admin-
istration was to be given to only patients who were 70 years
of age or less; the Osaka Medical Center protocol for TC
allowed few patients who were over 70 years of age. The
present comparative analysis was conducted only for those
patients who were 70 years of age or less. In all cases, che-
motherapy was performed only in those patients who were
expected to have an estimated remaining survival of greater
than 3 months.
Statistical analysis
MedCalc (MedCalc Software, Mariakerke, Belgium) was
used for the statistical analyses. The distribution of patients’
age, tumor histology and stage were analyzed by the Mann–
Whitney U-test, the Chi-square test, or Fisher’s exact test.
PFS and OS curves were constructed using the Kaplan–
Meier method and were evaluated for statistical signiWcance
by the log-rank test. The frequency of adverse eVects in the
two groups and the response of each chemotherapy were
compared by Fisher’s exact test. Results were considered to
be signiWcant when the p value was less than 0.05.
Results
Clinical characteristics of the patients with unresectable 
or recurrent disease who received TEC or TC 
chemotherapy as a remission induction therapy
TEC therapy was intended for 28 patients with unresectable
or recurrent disease at the Osaka University Hospital, and
TC therapy was attempted in 23 patients with similar dis-
eases at the Osaka Medical Center. Distributions of age,
histology and disease status did not exhibit any signiWcant
diVerences between the TEC and the TC groups (Table 1).
In the recurrent cases, all the patients underwent surgical
treatment as a Wrst treatment. The initial tumor stage in the
TEC group was Stage I in three cases, II in one case and III
in six cases; in the TC group it was I in Wve cases, II in two
cases, III in three cases and IV in one (p = 0.42 by the Chi-
square test). Adjuvant chemotherapy or radiation had been
performed postoperatively in 8 (80%) of 10 cases in TEC
group and 8 (73%) of 11 cases in TC group. TEC or TC
was administered as the Wrst treatment in all the recurrent
disease cases. In advanced cases with unresectable disease,
7 cases were at Stage III and 11 cases were in Stage IV in123
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were in Stage IV in the TC group, demonstrating no signiW-
cant diVerence (p = 0.88 by Fisher’s exact test).
Anti-tumor eVect of TEC and TC therapies in the patients 
with unresectable or recurrent disease
Complete response (CR) or PR was achieved in 14 of 18
(78%) and 6 of 12 (50%) advanced cases by TEC and TC,
respectively (p = 0.11 by Fisher’s exact test), and 5 of 10
(50%) and 6 of 11 (55%) recurrent cases by TEC and TC,
respectively (p = 0.83 by Fisher’s exact test) (Table 2). In
total, the response rate of TEC therapy against recurrent or
advanced diseases was 68% (19 of 28 cases), and that of
TC was 52% (12 of 23 cases). This 16% better diVerence in
response rates between TEC and TC therapies was not sta-
tistically signiWcant (p = 0.25 by Fisher’s exact test).
Survival eVect of TEC and TC therapies in the patients 
with unresectable or recurrent disease
Both OS and PFS did not demonstrate any signiWcant
diVerence between the TEC and TC groups (p = 0.63 for
OS and p = 0.55 for PFS, by the log-rank test) (Fig. 1). By
analyzing the eVect of TEC and TC on survival in sub-
groups of recurrent cases and advanced (unresectable)
cases, TEC therapy was demonstrated to be relatively more
eVective than TC in unresectable cases (p = 0.17 and
p = 0.75 for PFS and OS, respectively). TC therapy, on the
other hand, provided a better survival eVect than TEC in
recurrent cases (p = 0.32 and p = 0.22 for PFS and OS,
respectively), however these diVerences were not statisti-
cally signiWcant.
Clinical characteristics of the completely resected patients 
in Stage III/IV who received TEC or TC chemotherapy 
as an adjuvant therapy
Because in our previous study (submitted for publication),
we could not demonstrate a signiWcant survival improve-
ment in Stage I/II cases using TEC compared to radiation as
the adjuvant therapy, and because the eVects of TEC and
TC therapy on survival were not diVerent signiWcantly in
our present study, a comparison analysis of the survival
eVects of TEC and TC was focused completely on resected
Stage III and IV cases.
TEC was administered to 47 patients at the Osaka Uni-
versity Hospital, and TC to 30 patients at the Osaka Medi-
cal Center. Their clinical features are shown in Table 3.
Distributions of age, histology and stage did not exhibit any
signiWcant diVerence between the TEC and the TC groups.
The cases which were classiWed as being in Stage IIIa due
to positive peritoneal cytology alone (without any other risk
factors) were excluded from adjuvant chemotherapy, and
thus this study.
Survival eVect of adjuvant TEC and TC therapies 
in the completely resected patients in Stage III/IV
The OS and PFS curves of the TEC and TC groups were
shown in Fig. 2. The median follow-up period was
38 months (2–105 months). PFS exhibited a statistically
signiWcant diVerence between the TEC and TC groups
(p = 0.017 by the log-rank test, Hazard Ratio: 0.3838; 95%
CI: 0.1709–0.8623). Moreover, OS also exhibited a statisti-
cally signiWcant diVerence between TEC and TC groups
(p = 0.014 by the log-rank test, Hazard Ratio: 0.3108; 95%
CI: 0.1048–0.9214). Thus, TEC therapy was demonstrated
to provide a signiWcant improvement of survival as an adju-
vant therapy for resected Stage III/IV diseases.
Adverse eVects of TEC and TC therapies
Adverse eVects of the TEC and TC chemotherapies were
evaluated in 187 patients whose accurate data were avail-
able (Table 4).Hematological toxicity tended to be more
Table 1 Clinical characteristics of the advanced and recurrent cases
in which TEC or TC chemotherapy was performed as a remission
induction therapy
Clinical characteristics of the primary endometrial carcinoma cases
with unresectable diseases and the recurrent cases are shown. Distribu-
tions of age, histology and disease status did not exhibit any signiWcant
diVerences between the TEC and TC groups
Characteristic TEC (n = 28) TC (n = 23) p value
Age 57 (34–69) 56 (32–70) 0.95
Histology 0.54
Endometrioid 10 (36%) 7 (30%)
Non-endometrioid 18 (64%) 16 (70%)
Disease status 0.41
Advanced 18 (64%) 12 (52%)
Recurrent 10 (36%) 11 (48%)
Table 2 Anti-tumor eVect (response rate) of TEC and TC chemother-
apies
The anti-tumor eVect of TEC and TC was evaluated in advanced or
recurrent cases. Response rates were 68% in the TEC group and 52%
in the TC group. This diVerence was not statistically signiWcant
CR complete response, PR partial response, SD stable disease, PD
progressive disease
p = 0.25 (Fisher’s exact test)
Response to chemotherapy TEC (n = 28) TC (n = 23)
CR/PR 19 (68%) 12 (52%)
SD/PD 9 (32%) 11 (48%)123
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(p = 0.065); however, a statistical signiWcance was not
detected. Non-hematological toxicity was observed to be
similar in the TEC and TC groups (p = 0.49). The non-
accomplishment rates of the scheduled TEC and TC thera-
pies (due to severe toxicities) were not diVerent between
the two regimens (p = 0.81). Those due to the patients’
intermittent desire to stop chemotherapy were also not
statistically diVerent between the two regimens (p = 0.37).
Conclusions
Adjuvant chemotherapy for endometrial carcinoma is one
of the hottest topics in gynecologic oncology. Platinum,
anthracycline and taxane derivatives are regarded as critical
drugs for treatment of advanced or recurrent endometrial
carcinomas [4, 6, 7]. Although combination chemothera-
pies using these drugs, such as TAP, TEP and TEC, are
eVective, moderate-to-severe side eVects are sometimes
observed by Fleming et al. [8], Lissoni et al. [9], Papadimi-
triou et al. [10] and our previous study (Takata et al. [18]).
TC, which uses only paclitaxel and carboplatin, is the
current gold standard therapy for ovarian carcinoma due to
its high eVectiveness coupled with its high tolerability [17].
TC chemotherapy was somewhat eVective for endometrial
carcinoma [11–13]. It is, therefore, easy to understand why
TC, although not yet an established standard therapy, has
been frequently applied worldwide for the treatment of
endometrial carcinoma cases. However, until this current
work, a comparison of the usefulness of TC to other combi-
nation chemotherapies using these three key drugs, such as
TAP, TEP and TEC, has not been reported.
A GOG study to compare the combination of TC with
TAP (GOG #209) has Wnished recruitment of the patients;
however, analysis of the survival eVects of the two regi-
mens may require a few years; a similar JGOG study to
compare the combination chemotherapies TC, DP and AP
(JGOG #2043) is even less far along; it is still under regis-
tration of patients. Thus, our present study to address
whether anthracycline is still required in addition to TC
chemotherapy for successful treatment of Stage III/IV
endometrial carcinoma is quite important.
There are minor drawbacks to our study; it was a retro-
spective analysis of TC and TEC and thus was not the ideal,
which is a prospective randomized study. In addition, the
treatment data were from two center hospitals for gyneco-
logic malignancies; the Osaka University Hospital, in
which TEC regimen was conducted, and the Osaka Medical
Center for Cancer and Cardiovascular Diseases, in which
TC was used. Both hospitals shared common practices for
Fig. 1 PFS and OS of TEC and TC groups for unresectable or recur-
rent diseases. Both PFS and OS were not demonstrated to be signiW-
cantly diVerent between the TEC and TC groups (p = 0.63 and p = 0.55
by log-rank test, respectively). Solid line TEC group. Broken line TC
group
Table 3 Clinical characteristics of the completely resected Stages III
and IV patients to whom TEC or TC chemotherapy was performed as
an adjuvant therapy
The endometrial carcinomas, conWned to the uterus, which were
classiWed in Stage IIIa based on only positive peritoneal cytology, were
excluded. Distributions of age, histology and stage did not exhibit any
signiWcant diVerences between the TEC and TC groups
Characteristic TEC (n = 47) TC (n = 30) p value
Age 56 (3–69) 59 (34–70) 0.23
Histology 0.54
Endometrioid 33 (70%) 23 (77%)
Non-endometrioid 14 (30%) 7 (23%)
Stage 0.83
IIIa 14 (30%) 8 (27%)
IIIb 1 (2%) 1 (3%)
IIIc 26 (55%) 15 (50%)
IVb 6 (13%) 6 (20%)123
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dures. We believe that typical types of bias derived from a
retrospective study were minimized as much as possible.
The background features of the patients compared in the
current study were not signiWcantly diVerent between the
TC and TEC groups.
Comparison of the adverse eVects of the TEC and TC
chemotherapies showed that hematological toxicity, espe-
cially neutropenia, tended to be more frequently observed
in the TEC group than in the TC group (p = 0.065), how-
ever the neutropenia was tolerable when given G-CSF sup-
port. Non-hematological toxicity was observed similarly in
the TEC and TC groups (p = 0.49). These toxicities should
always be taken into consideration as part of the eVective-
ness of any chemotherapy.
Our previous study showed that signiWcant survival
improvement was not demonstrated using TEC compared
to radiation as an adjuvant therapy in Stage I/II cases (sub-
mitted), and the positive eVects of TEC and TC therapy on
survival were not signiWcantly diVerent in the present study,
indicating that TC therapy may take the place of an adju-
vant therapy for Stage I/II endometrial carcinoma.
Finding similar survival eVects for TC and TEC in the
most advanced and intractable unresectable cases and
recurrent cases (p = 0.63 for OS and p = 0.55 for PFS, by
the log-rank test) implied that TC may be used as a remis-
sion induction chemotherapy due to the abjectly poor prog-
nosis of those cases and the lower rate of severe side eVects
for TC therapy than for TEC. The tendency for improved
survival in recurrent cases following TC therapy (p = 0.32
and p = 0.22 for PFS and OS, respectively) compared to
TEC especially suggested that TC may be appropriate for
recurrent cases, too. On the other hand, in advanced unre-
sectable cases, TEC therapy tended to be more eVective
than TC (p = 0.17 for PFS). For these cases, although the
TEC may improve PFS, it will require G-CSF administra-
tion for its associated severe neutropenia. Alternatively, TC
may be proposed because, even though it is marginally less
eVective than TEC, it is more tolerable.
In the completely resected Stage III/IV cases, TEC
therapy was demonstrated to provide signiWcantly better
PFS than TC (p = 0.017 by the log-rank test, Hazard
Ratio: 0.3838; 95% CI: 0.1709–0.8623) and OS
(p = 0.014 by the log-rank test, Hazard Ratio: 0.3108;
95% CI: 0.1048–0.9214) with a median follow-up period
of 38 months (2–105 months). The reasons for these epic
results are uncertain as yet, although the synergistic or
additive eVect of a third drug mechanism is anticipated
to be the cause. The fact that TEC was much more eVec-
tive, especially for the completely resected cases in
Stage III/IV which were at high risk of recurrence, may
imply that the TEC regimen might play a role in not only
attacking the carcinoma cells forming the tumor mass
but also in killing remaining carcinoma stem cells and
metastases elsewhere, such as in the bone marrow, after
the complete resection of the tumor mass.
In this study, we proposed to question the apparent
increasing application of TC regimen to all forms of endo-
metrial carcinoma with an indication for chemotherapy.
Based on our results, TEC should be oVered as the pre-
ferred adjuvant therapy to Stage III/IV patients, after com-
plete surgical resection of their tumors. TEC may also be
eVective as a remission induction therapy for patients in
Fig. 2 PFS and OS of TEC and TC groups for adjuvant therapy (Stage III/IV). Both PFS and OS were signiWcantly better in the TEC group than
the TC group (p = 0.017 and p = 0.014 by the log-rank test, respectively). Solid line TEC group. Broken line TC group
Table 4 Adverse eVects of TEC and TC therapies
Grade of adverse eVects was based on the National Cancer Institute’s
Common Toxicity Criteria (version 2.0)
Toxicities TEC TC p value
Hematological (Grade 4) 67/115 (57%) 32/72 (44%) 0.065
Non-hematological 
(Grades 3, 4)
4/115 (3%) 4/72 (6%) 0.49123
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hand, the TC regimen may now be considered for listing as
a standard treatment useful for recurrent cases as a remis-
sion induction therapy having minimal side eVects, and for
patients in Stage I/II with risk factors requiring an adjuvant
therapy. We Wrmly believe that GOG #209 and JGOG
#2043 studies will provide strong evidence supporting our
Wndings and our proposals.
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